Pre-Transplant Testing

Combining Luminex xMAP technology with reverse sequence-specific oligonucleotide (rSSO) technology, high throughput DNA typing is achieved.

Our exclusive LMT feature premixed monoclonal antibodies and rabbit complement for a fast and dependable method of determining Class I or Class II antigens.

The LinkSēq line of real-time PCR products offers rapid genotyping of HLA and KIR with a simple workflow.

Amplify genomic DNA using SSP to determine HLA Class I and Class II alleles.

High-resolution typing of HLA alleles using SBT technique.

Our tissue typing family offers a host of HLA testing reagents optimized for use with our HLA typing trays.

Terasaki HLA Tissue Typing Trays contain well-characterized antisera that produce consistent and accurate HLA typing with complement-dependent cytotoxicity methods.

Anti-AT1R and anti-ETAR assays detect biomarker antibodies that form against angiotensin II type 1 receptors (AT1R) and endothelin receptors type A (ETAR).

Driven by the Luminex xMAP platform, our C1qScreen assay provides laboratories with a reliable tool for distinguishing between complement binding and non-complement binding antibodies.

A flow cytometry-based crossmatch assay optimized for the detection of leukocyte antibodies, combining traditional flow cytometry cellular crossmatch testing with the specificity of microbeads technology.

Designed for use in flow cytometric detection, a number of FlowPRA test options are available to screen human sera for antibodies, assigning percent PRA and antibody specificity for HLA Class I.

Our selection of LABScreen reagents use the Luminex xMAP platform in eight assays designed for precise determination of percent PRA in a broad range of targets.

Economical and convenient for screening patients, determining percent PRA and identifying antibodies. Terasaki trays are pre-coated with HLA Class I and Class II antigens designed to perform antibody detection based on ELISA techniques.

Panels frozen lymphocytes dispensed in Terasaki trays, designed to determine PRA and HLA antibody screening by complement-dependent cytotoxicity.